Literature DB >> 11117338

Brown recluse spider bites.

T P Forks1.   

Abstract

BACKGROUND: Brown recluse spider bites are a serious medical problem in the southeastern United States. Although most bites are asymptomatic, envenomation can result in a constellation of systemic symptoms referred to as loxoscelism. Patients can also develop necrotic skin ulcers (necrotic arachnidism). These ulcers are often difficult to heal and can require skin grafting or amputation of the bitten appendage.
METHODS: A search of the literature was performed using the search words "spider envenomation," "brown recluse spider bites," and "arachnid envenomation." RESULTS AND
CONCLUSIONS: Most brown recluse spider bites are asymptomatic. All bites should be thoroughly cleansed and tetanus status updated as needed. Patients who develop systemic symptoms require hospitalization. Surgical excision of skin lesions is indicated only for lesions that have stabilized and are no longer enlarging. Steroids are indicated in bites that are associated with severe skin lesions, loxoscelism, and in small children. Dapsone should be used only in adult patients who experience necrotic arachnidism and who have been screened for glucose-6-phosphate dehydrogenase deficiency. Topical nitroglycerin can be of value in decreasing the enlargement of necrotic skin ulcers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117338     DOI: 10.3122/15572625-13-6-415

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  2 in total

1.  Brown Recluse Spider Bites in Patients With Neutropenia: A Single-institution Experience.

Authors:  Diego R Hijano; Daniel Otterson; Maysam R Homsi; Yin Su; Li Tang; Jeannette Kirby; Miguela A Caniza
Journal:  J Pediatr Hematol Oncol       Date:  2019-01       Impact factor: 1.289

2.  Defining the complex phenotype of severe systemic loxoscelism using a large electronic health record cohort.

Authors:  Jamie R Robinson; Vanessa E Kennedy; Youssef Doss; Lisa Bastarache; Joshua Denny; Jeremy L Warner
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.